3-[3-[5-[(4-Methoxyphenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propanamide | 917911-36-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[3-[5-[(4-Methoxyphenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propanamide
• CAS: 917911-36-5
• 化学式: C₁₈H₁₈N₄O₄
• 分子量: 354.365
• InChiKey: ZUZWYCBBRXNFQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-[3-[5-[(4-Methoxyphenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propanamide 在 三乙基硅烷 、 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 、 lithium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-(3-(3-(5-Hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl)propanamido)cyclohex-1-enecarboxylic acid
  参考文献：
  名称：

  The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties

  摘要：

  Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.116
• 作为产物：
  描述：

  5-((4-甲氧基苄基)氧基)皮考啉腈 在 ammonium hydroxide 、 N-羟基丁二酰亚胺 、 羟胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 甲苯 为溶剂， 生成 3-[3-[5-[(4-Methoxyphenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propanamide
  参考文献：
  名称：

  The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties

  摘要：

  Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.116

文献信息

• Niacin receptor agonists, compositions containing such compounds and methods of treatment
  申请人：Raghavan Subharekha

  公开号：US20060293364A1

  公开（公告）日：2006-12-28

  The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了Formula I的化合物： 以及其药用可接受的盐和水合物，用于治疗动脉粥样硬化、血脂异常等疾病。药物组合物和使用方法也包括在内。
• Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
  申请人：Raghavan Subharekha

  公开号：US20100144778A1

  公开（公告）日：2010-06-10

  The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖式(I)的化合物，以及其药学上可接受的盐和水合物，用于治疗动脉粥样硬化、血脂异常等。还包括制药组合物和使用方法。
• US8168649B2
  申请人：——

  公开号：US8168649B2

  公开（公告）日：2012-05-01
• [EN] NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] AGONISTES DU RÉCEPTEUR DE LA NIACINE, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
  申请人：MERCK & CO INC

  公开号：WO2007002557A1

  公开（公告）日：2007-01-04

  [EN] The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
  [FR] La présente invention concerne des composés de formule (I) : de même que leurs sels ou leurs hydrates pharmaceutiquement acceptables, utilisables dans le traitement de l'athérosclérose, de la dyslipidémie et de maladies similaires. L'invention concerne également des compositions pharmaceutiques et des procédés d'utilisation.
• The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties
  作者：Jason E. Imbriglio、Daniel DiRocco、Rena Bodner、Subharekha Raghavan、Weichun Chen、Daria Marley、Craig Esser、Tom G. Holt、Michael S. Wolff、Andrew K.P. Taggart、M. Gerard Waters、James R. Tata、Steven L. Colletti

  DOI：10.1016/j.bmcl.2010.11.116

  日期：2011.5

  Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties. (C) 2010 Elsevier Ltd. All rights reserved.